A decade after Keytruda hit the market, Merck has now said a subcutaneous version of the immunotherapy passed a ...
Merck's new formulation could help secure a larger share of Keytruda's sales after the cancer drug's U.S. patent expires in ...
Merck & Co.’ Inc.’s stock MRK rose 2% premarket Tuesday, after the company reported positive results for a new formulation of its blockbuster cancer drug Keytruda. Rahway, N.J.-based Merck said a ...
Merck said on Tuesday a study showed that its injectable version of cancer drug Keytruda was not inferior to the currently ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the ...
Merck (MRK) stock gains as its subcutaneously delivered pembrolizumab meets key goals in Phase 3 trial against intravenous ...
The CHMP renders a positive opinion recommending approval for MRK's Keytruda for the first-line treatment of malignant ...
We recently compiled a list of the 10 Best Immunotherapy Stocks to Buy Now. In this article, we are going to take a look at ...
Actively Exploring Partnership for Alzheimer’s DevelopmentSupplementary Financing Concluded in Q4ROCHESTER, N.Y., Nov. 18, 2024 (GLOBE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback